


Product: CAL-101 (GS-1101)**ALTERNATE NAME:** 5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone; Idealisib**CATALOG #:** 2613-5, 25**AMOUNT:** 5 mg, 25 mg**STRUCTURE:****MOLECULAR FORMULA:** C₂₂H₁₈FN₇O**MOLECULAR WEIGHT:** 415.42**CAS No.** 870281-82-6**APPEARANCE:** White solid**SOLUBILITY:** DMSO (~ 25 mg/ml) or EtOH (~ 15 mg/ml)**PURITY:** >98% by HPLC**STORAGE:** Store at -20°C. Protect from air and light**DESCRIPTION:** CAL-101 is a cell-permeable inhibitor of the PI3K catalytic subunit p110 δ (IC₅₀ = 2.5 nM) that displays 40- to 300-fold selectivity against other PI3K class I enzymes (IC_{50s} = 820, 565, and 89 nM for p110 α , β , and γ , respectively). It has also been shown to inhibit the chemotaxis of chronic lymphocytic leukemia cells and to downregulate the secretion of chemokines triggered by B-cell receptor signaling.**REFERENCES:** Lannutti, B.H., *et al.* (2011). *Blood* **117**, 591-594.**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**

AS-604850 (Cat. No. 2339-1, 5)
BAG956 (Cat.No. 2456-5, 25)
BEZ235 (NVP-BEZ235) (Cat. No. 1626-5, 25)
GDC-0941 bismesylate (Cat. No. 1623-1, 5)
Deforolimus (Cat. No. 1587-5, 25)
DiscoveryPak™ PI 3-Kinase Inhibitor Panel (Cat. No. K856-5)
GDC-0941 (Cat. No. 1623-1,5)
IC87114 (Cat. No. 1661-1)
IPI-145 (Cat. No. 2445-5, 25)
LY 294002 (Cat. No. 1667-5, 25)
mTOR Inhibitor, Ku-0063794 (Cat. No. 1779-1,5)
OSU-03012, hydrochloride (Cat. No. 2295-5, 25)
PI-103 (Cat. No. 1728-1,5)
PIK-294 (Cat. No. 2614-5, 25)
PI3-K γ Inhibitor, AS-605240 (Cat. No. 1780-1,5)
PathwayReady™ PI3-K/Akt/mTOR Signaling Inhibitor panel (Cat. No. K857-11)
PP242 (Cat. No. 1658-1)
PX-866 (Cat. No. 1965-1, 5)
Rapamycin (Cat. No. 1568-5, 50)
Temsirrolimus (Cat. No. 1600-5, 25)
TGX-115 (Cat. No. 1660-1)
TGX-221 (Cat. No. 1781-1,5)
Wortmannin (Cat. No. 1670-1)
YM201636 (Cat. No. 2045-1, 5)

FOR RESEARCH USE ONLY! Not to be used in humans.